Search Results
Transient suppressor CELLULAR DIE PACKAGE, 15KCD47 Datasheet, 15KCD47 circuit, 15KCD47 data sheet : MICROSEMI, alldatasheet, Datasheet, Datasheet search site for Electronic Components and Semiconductors, integrated circuits, diodes, triacs and other semiconductors.
- 15KCD47 Click to view
- 2 Pages
- 123.25 Kbytes
- 15KCD47
Oct 30, 2021 · CD47 is an important tumor antigen for the development and progression of various cancers. The interaction of CD47 with SIRPα triggers a "don't eat me" signal to the macrophages, inhibiting phagocytosis. Thus, overexpression of CD47 enables tumor cells to evade immune surveillance via the blockade of phagocytic mechanisms.
- Zhongxing Jiang, Hao Sun, Jifeng Yu, Jifeng Yu, Wenzhi Tian, Yongping Song
- 10.1186/s13045-021-01197-w
- 2021
- J Hematol Oncol. 2021; 14: 180.
People also ask
How important is CD47 in cancer prognosis?
Does high CD47 expression correlate with a poor outcome?
What is cluster of Differentiation 47 (CD47)?
Does a CD47 deficiency promote self-renewal and reprogramming in endothelial cells?
Sep 10, 2020 · CD47 is overexpressed in various types of cancers and it can directly bind with SIRPα, which is mainly located on macrophages. The binding of CD47-SIRPα transmits a “don't eat me” signal, which can prevent cancer cells from immune clearance.
- Can-Yu Huang, Zi-Han Ye, Mu-Yang Huang, Jin-Jian Lu
- 10.1016/j.tranon.2020.100862
- 2020
- Transl Oncol. 2020 Dec; 13(12): 100862.
Oct 28, 2023 · CD47 is highly expressed in cancers to prevent phagocytosis by phagocytes. •. Targeting CD47 has been verified as a promising therapeutic strategy in cancer immunotherapy. •. Antibodies and small molecules targeting CD47 exhibited both safety and efficacy in clinical trials. •.
- CD47 Monoclonal Antibodies
- Imm0306
- Tg-1801
- Sirpα/Fc Fusion Protein Antibodies
CC-90002
CC-90002 is the first generation of humanized IgG4 anti-CD47 antibody entering clinical research. CC-90002 plus rituximab (an anti-CD20 monoclonal antibody) demonstrated tolerability and modest clinical activity in the heavily pretreated relapsed/refractory (R/R) NHL patients . AEs were predominantly Grade 1/2, and the most frequent Grade 3/4 AEs were neutropenia (38%) and thrombocytopenia (21%). Twenty-four subjects were treated, one subject attained a stable complete response rate (CR),...
Hu5F9-G4
Hu5F9-G4 (5F9), also known as magrolimab, is a humanized monoclonal IgG4 antibody that was independently developed by Stanford University Forty Seven (Stanford, CA, USA) . 5F9 not only inhibits CD47 signaling, which increases macrophage phagocytosis, but also stimulates ADCC . Studies have demonstrated that 5F9 was more effective in combination with other antibodies than alone in the treatment of non-Hodgkin lymphoma [1, 43, 51, 52]. A phase Ib study (NCT02953509) assessed the safety...
TJ011133
TJ011133 (TJC4, also known as lemzoparlimab) is a therapeutic anti-CD47 IgG4 antibody of the next generation investigated by I-Mab Biopharma (Beijing, China). TJ011133 has a unique binding epitope and an RBC/platelet sparing characteristic; therefore it does not produce substantial hematologic toxicity and does not require priming doses like 5F9 . Eight R/R patients with CD20-positive NHL who had received at least two prior lines of therapy were included in a Phase Ib research (NCT0393481...
Both in vivo and in vitro experiments confirmed that comparing with CD47 monoclonal antibodies, anti-CD47/CD20 bispecific antibodies showed better binding preference to tumor cells and more potent anti-lymphoma activity [54, 55]. Researchers suggest that anti-CD47/CD20 bispecific antibodies might be viable candidates for clinical trials, in which I...
TG-1801 is an investigational first-in-class, bispecific anti-CD47/CD19 monoclonal antibody. TG-1801 has exhibited a potent capability to induce ADCP and ADCC in malignant B-cell lines and primary tumor B-cells from patients with ALL, CLL, and different subtypes of NHL in preclinical studies . TG-1801 combined with rituximab was observed to have a ...
TTI-621
TTI-621 is a fusion protein developed from the CD47 binding domain of human SIRPα linked to the Fc region of human IgG1. It is intended to improve phagocytosis and anti-cancer activity of macrophages by preventing CD47-SIRPα interaction between malignant cells and macrophages through Fc receptors engagement . In preclinical studies, TTI-621 was shown to enhance macrophage phagocytosis of various malignant cells and decreased the growth of AML and B-cell lymphoma in xenografts. Besides, TT...
TTI-622
Like TTI-621, TTI-622 is a soluble SIRPα/Fc variant protein containing an IgG4 Fc tail. TTI-622 resulted in a statistically significant tumor growth reduction and improved survival in both early and delayed treatment in DLBCL xenograft tumor model. TTI-622 monotherapy showed partial tumor growth inhibition in Burkitt lymphoma and in MM xenograft models. Additionally, the therapeutic effect was further enhanced when TTI-622 was combined with daratumumab (an anti-CD38 antibody). Importantly, TT...
ALX148
ALX148 (also known as evorpacept) is a new CD47-blocking molecule produced by connecting a modified SIRPα D1 domain to an inactive human IgG1 Fc. ALX148 exhibits a high affinity for CD47 in many species, inhibits wild-type SIRPα binding, and promotes tumor cell phagocytosis by macrophages. ALX148 had little effect on normal blood cells in experiments with rodents and NHPs. In addition, ALX148 enhanced anti-cancer activity of obinutuzumab and rituximab (both anti-CD20 antibodies) in carcinogen...
Jun 13, 2022 · Zhenjie Yi, Liyang Zhang, Siqi Fu & Yu Zeng. Scientific Reports 12, Article number: 9803 ( 2022 ) Cite this article. 8738 Accesses. 12 Citations. Metrics. CD47 performs a vital function in cancer...
Nov 15, 2023 · CD47, a cell surface protein, has been identified as a crucial regulator of the TME and a potential therapeutic target for cancer therapy. However, the precise functions and implications of CD47 in the TME during immunotherapy for cancer patients remain incompletely understood.
